Original Article

You have full text access to this OnlineOpen article

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

  1. Srdan Verstovsek M.D.1,
  2. Mirna Golemovic M.D.1,
  3. Hagop Kantarjian M.D.1,
  4. Tashi Manshouri M.D.1,
  5. Zeev Estrov M.D.1,
  6. Paul Manley Ph.D.2,†,
  7. Tong Sun M.D.3,
  8. Ralph B. Arlinghaus M.D.3,
  9. Leila Alland M.D.2,‡,
  10. Margaret Dugan M.D.2,§,
  11. Jorge Cortes M.D.1,
  12. Francis Giles M.D.1,
  13. Miloslav Beran M.D.1,¶,*

Article first published online: 2 AUG 2005

DOI: 10.1002/cncr.21299

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1230–1236, 15 September 2005

Additional Information

How to Cite

Verstovsek, S., Golemovic, M., Kantarjian, H., Manshouri, T., Estrov, Z., Manley, P., Sun, T., Arlinghaus, R. B., Alland, L., Dugan, M., Cortes, J., Giles, F. and Beran, M. (2005), AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer, 104: 1230–1236. doi: 10.1002/cncr.21299

Author Information

  1. 1

    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Novartis Institutes for Biomedical Research, Basel, Switzerland

  3. 3

    Department of Molecular Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Dr. Manley is a full-time employee of Novartis.

  2. ‡

    Dr. Alland is an employee of Novartis and owns stock in the company.

  3. §

    Dr. Dugan is an employee of Novartis.

  4. Fax: (713) 794-4297

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Unit 428, P.O. Box 301402, Houston, TX 77230

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 2 AUG 2005
  3. Manuscript Accepted: 14 APR 2005
  4. Manuscript Revised: 6 APR 2005
  5. Manuscript Received: 15 DEC 2004

Funded by

  • Novartis

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (224K)

REFERENCES

  • 1
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561–566.
  • 2
    Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998; 4: 1661–1672.
  • 3
    Kantarjian H, Sawyers C, Hochhaus A, et al. International STI571 CML Study Group. Hematological and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645–652.
  • 4
    Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103: 2873–2878.
  • 5
    Hoelzer D, Gokbuget N, Ottmann OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol. 2002; 39: 32–37.
  • 6
    Ottman OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100: 1965–1971.
  • 7
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876–880.
  • 8
    Corbin AS, La Rosee P, Stoffregen EP, Drucker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003; 101: 4611–4614.
  • 9
    Cowan-Jacob SW, Guez V, Griffin JD, et al. Bcr-Abl kinase mutations and drug resistance to imatinib (STI571) in chronic myelogenous leukemia. Mini Rev Med Chem. 2004; 4: 285–299.
  • 10
    Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001; 293: 2163.
  • 11
    Ricci C, Scappini B, Divoky V, et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res. 2002; 62: 5995–5998.
  • 12
    Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000; 95: 1758–1766.
  • 13
    Mahon FX, Deininger MB, Schultheis B, Chabrol Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000; 96: 1070–1079.
  • 14
    Scappini B, Gatto S, Onida F, et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer. 2004; 100: 1459–1471.
    Direct Link:
  • 15
    Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat. 2003; 6: 231–238.
  • 16
    Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004; 11: 35–43.
  • 17
    Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers DL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399–401.
  • 18
    Weisberg E, Manley P, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7: 129–141.
  • 19
    Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005; 11: 4941–4947.
  • 20
    Estrov Z, Talpaz M, Zipf TF, et al. Role of GM-CSF in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL): studies on two newly established Ph1-positive cell lines (Z-119 and Z-181). J Cell Physiol. 1996; 166: 618–630.
    Direct Link:
  • 21
    Beran M, Pisa P, O'Brien S, et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993; 53: 3603–3610.
  • 22
    Giles F, Kantarjian H, Wassmann B, et al. A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of Bcr/Abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL) [abstract]. Blood. 2004; 104: 10a–11a.
View Full Article (HTML) Get PDF (224K)